Introduction
Patients and methods
Eligibility criteria
Definition of both anthracycline and taxane resistance
Therapy
Assessment
Statistical analysis
Results
Patients characteristics
No. of patients | % | |
---|---|---|
No. | 38 | |
Age, years | ||
Median | 53 | |
Range | 30–69 | |
Performance statusa
| ||
0 | 31 | 81.6 |
1 | 5 | 13.2 |
2 | 2 | 5.3 |
Menopausal status | ||
Premenopause | 12 | 31.6 |
Postmenopause | 26 | 68.4 |
Receptor status | ||
Estrogen receptor | ||
Positive | 7 | 18.4 |
Negative | 31 | 81.6 |
Progesterone receptor | ||
Positive | 6 | 15.8 |
Negative | 31 | 81.6 |
Unknown | 1 | 2.6 |
Resistance to previous chemotherapies (Anthracycline/Taxane) | ||
Primary resistance/Primary resistance | 7 | 18.4 |
Primary resistance/Secondary resistance | 11 | 29.0 |
Secondary resistance/Primary resistance | 6 | 15.8 |
Secondary resistance/Secondary resistance | 11 | 29.0 |
Unknown | 3 | 7.9 |
Prior trastuzumab | ||
Yes | 30 | 78.9 |
No | 8 | 21.2 |
Histology | ||
Invasive ductal carcinomas | 34 | 89.5 |
Other | 3 | 7.9 |
Unknown | 1 | 2.6 |
Number of metastasis | ||
1 | 27 | 71.1 |
≥2 | 10 | 26.3 |
Unknown | 1 | 2.6 |
Primary metastatic sites | ||
Lung | 17 | 44.7 |
Liver | 10 | 26.3 |
Bone | 5 | 13.2 |
Skin | 2 | 5.3 |
Peritoneum | 1 | 2.6 |
Mediastinum | 1 | 2.6 |
Pleura | 1 | 2.6 |
Unknown | 1 | 2.6 |
Treatment activity
Response | No. of Patients | % |
---|---|---|
Complete response | 2 | 5.3 |
Partial response | 5 | 13.2 |
Stable disease | 20 | 52.6 |
Progressive disease | 8 | 21.1 |
Not evaluated | 3 | 7.9 |
Response rate | 18.4% (95% CI, 7.7–34.3%) | |
Clinical benefit rate (CBR = CR + PR + SD >/=24 weeks) | 21.1% (95% CI, 9.6–37.3%) |
Anthracycline or taxane resistance and response to capecitabine and trastuzumab combination chemotherapy
Anthracycline/Taxane | Primary resistance/Primary resistance | Primary resistance/Secondary resistance | Secondary resistance/Primary resistance | Secondary resistance/Secondary resistance |
---|---|---|---|---|
No. of patients | 7 | 11 | 6 | 11 |
Response rate (%) | 1/7 (14.3) | 2/11(18.2) | 2/6 (33.3) | 1/11(9.1) |
95% CI | 0.4–57.9 | 2.3–51.8 | 4.3–77.7 | 0.2–41.3 |
Toxicity
Toxicity gradea
| Grade 1 | Grade 2 | Grade 3 | Grade 4 |
---|---|---|---|---|
No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | |
Hematological toxicity | ||||
Anemia | 1 (2.6) | 7 (18.4) | 0 | 0 |
Leucocytopenia | 1 (2.6) | 6 (15.8) | 0 | 0 |
Neutropenia | 11 (28.9) | 6 (15.8) | 2 (5.3) | 0 |
Thrombocytopenia | 2 (5.3) | 0 | 0 | 0 |
Elevated ALP | 17 (44.7) | 2 (5.3) | 0 | 0 |
Elevated AST | 14 (36.8) | 3 (7.9) | 0 | 0 |
Elevated ALT | 12 (31.6) | 1 (2.6) | 0 | 0 |
Elevated γ-GTP | 8 (21.1) | 3 (7.9) | 2 (5.3) | 0 |
Elevated T-Bil | 11 (28.9) | 5 (13.2) | 0 | 0 |
Elevated creatinine | 1 (2.6) | 0 | 0 | 0 |
Hypercalcemia | 16 (42.1) | 1 (2.6) | 0 | 0 |
Hypoalbuminemia | 12 (31.6) | 0 | 0 | 0 |
Nonhematological toxicity | ||||
Hand–foot syndrome | 16 (42.1) | 5 (13.2) | 3 (7.9) | 0 |
Mucositis | 11 (28.9) | 0 | 0 | 0 |
Nausea | 8 (21.1) | 0 | 0 | 0 |
Vomiting | 4 (10.5) | 0 | 0 | 0 |
Diarrhea | 7 (18.4) | 1 (2.6) | 1 (2.6) | 0 |
Constipation | 0 | 0 | 1 (2.6) | 0 |
Abdominal pain | 1 (2.6) | 0 | 0 | 0 |
Edema | 3 (7.9) | 0 | 0 | 0 |
Rash | 1 (2.6) | 0 | 0 | 0 |
Hyperpigmentation | 5 (13.2) | 0 | 0 | 0 |
Pruritus | 1 (2.6) | 0 | 0 | 0 |
Injection site reaction | 1 (2.6) | 0 | 0 | 0 |
Nail changes | 1 (2.6) | 1 (2.6) | 0 | 0 |
Ulceration | 1 (2.6) | 0 | 0 | 0 |
Cervical pain | 1 (2.6) | 0 | 0 | 0 |
Chest pain | 2 (5.3) | 0 | 0 | 0 |
Cough | 2 (5.3) | 1 (2.6) | 0 | 0 |
Sputum | 0 | 1 (2.6) | 0 | 0 |
Dyspnea | 0 | 1 (2.6) | 0 | 0 |
Fever | 3 (7.9) | 1 (2.6) | 0 | 0 |
Fatigue | 10 (26.3) | 2 (5.3) | 0 | 0 |
Appetite loss | 2 (5.3) | 1 (2.6) | 0 | 0 |
Weight loss | 0 | 1 (2.6) | 0 | 0 |
Headache | 5 (13.2) | 0 | 0 | 0 |
Dizziness | 1 (2.6) | 0 | 0 | 0 |
Voice changes | 1 (2.6) | 0 | 0 | 0 |
Impaired motor function | 4 (10.5) | 0 | 0 | 0 |
Photophobia | 0 | 1 (2.6) | 0 | 0 |
Cataract | 0 | 1 (2.6) | 0 | 0 |
Back pain | 1 (2.6) | 0 | 0 | 0 |
Urinary retention | 1 (2.6) | 0 | 0 | 0 |
Pain on urination | 1 (2.6) | 0 | 0 | 0 |